Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04092712 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers
A Phase 1 study, sponsored by Concert Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04092712 is a Phase 1 study that has completed, run by Concert Pharmaceuticals. The registered enrollment target is 6 participants.
The verdict
NCT04092712, a Phase 1 study, has completed, sponsored by Concert Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of \[14C\]-CTP-543 in healthy male subjects.
Interventions
- DRUG [14C]-CTP-543
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2019-09-05 |
| Est. Completion | 2019-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04092712
The ClinicalTrials.gov registry entry for NCT04092712 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Concert Pharmaceuticals, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [14C]-CTP-543 is the first listed.
NCT04092712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04092712 about?
NCT04092712 is a clinical study titled "Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers". This study will assess the absorption, metabolism, excretion, mass balance, safety, and tolerability of a single oral administration of \[14C\]-CTP-543 in healthy male subjects.
What is the current status of trial NCT04092712?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2019-09-05. Estimated completion is 2019-09-20.
What interventions are being tested in trial NCT04092712?
The interventions under investigation include: [14C]-CTP-543 (DRUG).
Who is sponsoring clinical trial NCT04092712?
This trial is sponsored by Concert Pharmaceuticals, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.